Design and immunogenicity of a quadrivalent mRNA vaccine targeting HSV-2 with comparative evaluation of co-formulated and admixed formulations.

ABSTRACT:

Introduction

The globally prevalent herpes simplex virus 2 (HSV-2) establishes lifelong latent infections in sensory neurons and causes recurrent genital disease. However, no vaccine is available to prevent HSV-2 infection. The mRNA vaccine platform offers distinct advantages over protein-based approaches, including rapid antigen design, scalable production, and efficient intracellular expression.

Methods

A prophylactic quadrivalent mRNA vaccine encoding full-length HSV-2 glycoprotein B (gB2), C (gC2), D (gD2), and E (gE2) was developed. Its immunogenicity and protective efficacy were evaluated in a murine intravaginal challenge model.

Results

Quadrivalent mRNA vaccine-immunized mice showed robust HSV-2-specific immune responses, including high titers of neutralizing

SUBMITTER: Cho Y 

PROVIDER: S-EPMC12714894 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature